logo
logo

Help Therapeutics Completes Series C Financing Of 25 Million Dollars

Nov 29, 2021•almost 4 years ago

Round Type

series c

Nanjing

Description

Recently, the iPSC therapeutics leading global platform company - Help Therapeutics announced the completion of Series C financing of 25 millions of dollars. This round of financing was led by Ming Bioventures, followed by Share Capital, Beisen Medical Fund, and Jolmo Capital, with additional support from our old shareholder Purple Bull Startups, and Hoyue Capital acting as the exclusive financial advisor for this round of financing. The financing will help the company conduct and complete clinical trials of its fully independent intellectual property development pipeline, iPSC heart cell injection, and will initiate clinical studies of immune cell therapy based on iPSC technology within the next year.

Company Information

Company

Help Therapeutics

Location

Nanjing, Jiangsu, China

About

Recently, the iPSC therapeutics leading global platform company - Help Therapeutics announced the completion of Series C financing of 25 millions of dollars. The financing will help the company conduct and complete clinical trials of its fully independent intellectual property development pipeline, iPSC heart cell injection, and will initiate clinical studies of immune cell therapy based on iPSC technology within the next year.Help Therapeutics After years of development, the company has developed several product pipelines based on iPSC technology, mastering advanced iPSC reprogramming technology while having the capability of large-scale automated production and cell quality inspection of The company has already obtained the first iPSC technology-based heart failure cell therapy clinical study filing from the National Health Care Commission in China, and is also actively preparing clinical registration filings for both the U.S. and China for its heart failure treatment pipeline. Help Therapeutics is at the forefront of the world's technology in terms of cell mass production and quality assurance.